<- Go Home

Dyax Corp.

Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders.

Market Cap

$5.7B

Volume

1.7M

Cash and Equivalents

$94.6M

EBITDA

-$43.2M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$11.8M

Profit Margin

13.57%

52 Week High

$38.56

52 Week Low

$14.06

Dividend

N/A

Price / Book Value

19.69

Price / Earnings

-91.10

Price / Tangible Book Value

19.69

Enterprise Value

N/A

Enterprise Value / EBITDA

N/A

Operating Income

-$44.3M

Return on Equity

-30.88%

Return on Assets

-9.99

Cash and Short Term Investments

$294.4M

Debt

N/A

Equity

$287.2M

Revenue

$87.1M

Unlevered FCF

$11.5M

Sector

Biotechnology

Category

N/A

Company Stock Pitches